682 related articles for article (PubMed ID: 19568229)
1. The extent and determinants of prescribing and adherence with acid-reducing medications: a national claims database study.
El-Serag HB; Fitzgerald S; Richardson P
Am J Gastroenterol; 2009 Sep; 104(9):2161-7. PubMed ID: 19568229
[TBL] [Abstract][Full Text] [Related]
2. The use of acid-decreasing medication in veteran patients with gastro-oesophageal reflux disorder with and without Barrett's oesophagus.
El-Serag HB; Wieman M; Richardson P
Aliment Pharmacol Ther; 2008 Jun; 27(12):1293-9. PubMed ID: 18363892
[TBL] [Abstract][Full Text] [Related]
3. Treatment patterns and symptom control in patients with GERD: US community-based survey.
Chey WD; Mody RR; Wu EQ; Chen L; Kothari S; Persson B; Beaulieu N; Lu M
Curr Med Res Opin; 2009 Aug; 25(8):1869-78. PubMed ID: 19530980
[TBL] [Abstract][Full Text] [Related]
4. Prescribing proton pump inhibitors for initial treatment of acid-related gastrointestinal diseases in a managed care population.
Chan J; Hui RL; Szpakowski JL
Am J Manag Care; 2004 Jul; 10(7 Pt 1):433-41. PubMed ID: 15298365
[TBL] [Abstract][Full Text] [Related]
5. Primary-care physicians' perceptions and practices on the management of GERD: results of a national survey.
Chey WD; Inadomi JM; Booher AM; Sharma VK; Fendrick AM; Howden CW
Am J Gastroenterol; 2005 Jun; 100(6):1237-42. PubMed ID: 15929751
[TBL] [Abstract][Full Text] [Related]
6. A practice-based approach for converting from proton pump inhibitors to less costly therapy.
Lucas LM; Gerrity MS; Anderson T
Eff Clin Pract; 2001; 4(6):263-70. PubMed ID: 11769299
[TBL] [Abstract][Full Text] [Related]
7. Diagnosis and treatment of gastroesophageal reflux disease in Ohio Medicaid patients: practice patterns and temporal trends.
Cooper GS; Mourad WA; Koroukian SM
Pharmacoepidemiol Drug Saf; 2004 Jan; 13(1):21-7. PubMed ID: 14971119
[TBL] [Abstract][Full Text] [Related]
8. A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease.
Gerson LB; Robbins AS; Garber A; Hornberger J; Triadafilopoulos G
Am J Gastroenterol; 2000 Feb; 95(2):395-407. PubMed ID: 10685741
[TBL] [Abstract][Full Text] [Related]
9. Proton pump inhibitor utilization patterns in infants.
Barron JJ; Tan H; Spalding J; Bakst AW; Singer J
J Pediatr Gastroenterol Nutr; 2007 Oct; 45(4):421-7. PubMed ID: 18030207
[TBL] [Abstract][Full Text] [Related]
10. Proton pump inhibitors. Compliance with a mandated step-up program.
Mamdani MM; Tu K; Jaakkimainen L; Bica A; Hux J
Can Fam Physician; 2001 Mar; 47():531-5. PubMed ID: 11281086
[TBL] [Abstract][Full Text] [Related]
11. A cost analysis of outpatient care for patients with Barrett's esophagus in a managed care setting.
Eloubeidi MA; Homan RK; Martz MD; Theobald KE; Provenzale D
Am J Gastroenterol; 1999 Aug; 94(8):2033-6. PubMed ID: 10445524
[TBL] [Abstract][Full Text] [Related]
12. The length of newly diagnosed Barrett's oesophagus and prior use of acid suppressive therapy.
El-Serag HB; Aguirre T; Kuebeler M; Sampliner RE
Aliment Pharmacol Ther; 2004 Jun; 19(12):1255-60. PubMed ID: 15191506
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of use of proton pump inhibitors in Greece.
Ntaios G; Chatzinikolaou A; Kaiafa G; Savopoulos C; Hatzitolios A; Karamitsos D
Eur J Intern Med; 2009 Mar; 20(2):171-3. PubMed ID: 19327607
[TBL] [Abstract][Full Text] [Related]
14. Large variations in prescriptions of gastrointestinal medications in hemodialysis patients on three continents: the Dialysis Outcomes and Practice Patterns Study (DOPPS).
Bailie GR; Mason NA; Elder SJ; Andreucci VE; Greenwood RN; Akiba T; Saito A; Bragg-Gresham JL; Gillespie BW; Young EW
Hemodial Int; 2006 Apr; 10(2):180-8. PubMed ID: 16623672
[TBL] [Abstract][Full Text] [Related]
15. Temporal trends of Barrett's oesophagus and gastro-oesophageal reflux and related oesophageal cancer over a 10-year period in England and Wales and associated proton pump inhibitor and H2RA prescriptions: a GPRD study.
Alexandropoulou K; van Vlymen J; Reid F; Poullis A; Kang JY
Eur J Gastroenterol Hepatol; 2013 Jan; 25(1):15-21. PubMed ID: 23022985
[TBL] [Abstract][Full Text] [Related]
16. [Barrett esophagus: modern diagnosis, drug therapy and reduce risk of cancer].
Kashin SV; Ivanikov IO
Eksp Klin Gastroenterol; 2009; (2):90-8. PubMed ID: 19552026
[TBL] [Abstract][Full Text] [Related]
17. Gastroesophageal reflux disease in primary care: using changes in proton pump inhibitor therapy as an indicator of partial response.
Ruigómez A; Johansson S; Wernersson B; Fernández Cantero O; García Rodríguez LA
Scand J Gastroenterol; 2012 Jul; 47(7):751-61. PubMed ID: 22519917
[TBL] [Abstract][Full Text] [Related]
18. Healthcare costs of GERD and acid-related conditions in pediatric patients, with comparison between histamine-2 receptor antagonists and proton pump inhibitors.
Kothari S; Nelson SP; Wu EQ; Beaulieu N; McHale JM; Dabbous OH
Curr Med Res Opin; 2009 Nov; 25(11):2703-9. PubMed ID: 19775195
[TBL] [Abstract][Full Text] [Related]
19. Gastroprotective drugs in Australia: utilization patterns between 1997 and 2006 in relation to NSAID prescribing.
Barozzi N; Tett SE
Clin Ther; 2009 Apr; 31(4):849-61. PubMed ID: 19446158
[TBL] [Abstract][Full Text] [Related]
20. Non-cardiac chest pain: the long-term natural history and comparison with gastroesophageal reflux disease.
Williams JF; Sontag SJ; Schnell T; Leya J
Am J Gastroenterol; 2009 Sep; 104(9):2145-52. PubMed ID: 19513020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
